-
2022-503136-13-00
1
2024-02-29
various B-cell malignancies
-
2023-505604-32-00
5
2024-01-24
Non small cell lung cancer (NSCLC)
-
2023-504196-24-00
5
2023-10-17
osteogenesis imperfecta
-
2023-508218-41-00
5
2023-08-17
Autosomal Recessive Polycystic Kidney Disease
-
2022-500544-38-00
5
2023-06-05
Advanced Breast Cancer
-
2023-509335-60-00
1
2023-02-23
Advanced solid tumors including (but not limited to), non-small cell l
-
2023-507031-38-00
5
2023-01-09
Severe viral lung infections
-
2022-501152-28-00
4
2022-12-21
Breast Cancer
-
2022-502503-30-00
5
2022-12-15
Acute lymphoblastic leukemia
-
2022-501374-19-00
4
2022-09-16
Aggressive and Indolent B-cell Malignancies (mantle cell lymphoma; chr
-
2024-516066-11-00
5
2022-08-31
Patients with newly diagnosed, histologically confirmed, primary advan
-
2022-503012-16-00
5
2022-07-20
Patients on treatment with Factor Xa Inhibitor needing for an urgent i
-
2024-513185-19-00
9
2022-07-13
Extensive stage small cell lung cancer (ES-SCLC)
-
2023-506414-46-00
5
2022-04-22
High risk patients defined as having at least one of the following ris
-
2024-514617-35-00
4
2021-12-20
Progressive forms of Multiple Sclerosis
-
2024-511469-13-00
4
2021-10-19
Fibrodysplasia Ossificans Progressiva
-
2023-509138-21-00
5
2021-08-26
Pulmonary Arterial Hypertension (PAH)
-
2023-509331-83-00
5
2021-07-28
complement 3 glomerulopathy
-
2022-501677-39-00
5
2021-05-25
Adolescent Renal Allografts
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2023-506471-10-00
5
2019-10-04
Secondary hyperparathyroidism (SHPT) in pediatric patients with chroni
-
2025-523845-90-00
3
2026-06-09
Relapsed/Refractory Hematologic Autoimmune Disease
-
2025-522099-10-00
4
2026-06-05
Pathologically prevascularized corneas due to herpetic keratopathy pri
-
2024-520138-31-00
4
2026-06-01
Early-stage favorable classic Hodgkin lymphoma